AstraZeneca trials show antibody is over 80% effective in preventing COVID-19 – .

0
14
AstraZeneca trials show antibody is over 80% effective in preventing COVID-19 – .


COVID-19 vaccine maker AstraZeneca announced Thursday that its antibody is more than 80% effective in reducing the risk of serious illness or death.

The company said new data from Phase III trials on the prevention and outpatient treatment of AZD7442 COVID-19 Provent showed “robust efficacy” from a single intramuscular dose of the combination of antibodies to long-acting (LAAB).

FAUCI: COVID-19 HOSPITALIZATIONS ON THE RISE AMONG VACCINATED

Analysis of the ongoing Provent trial with six-month follow-up found that a 300 mg intramuscular dose of AZD7442 reduced the risk of developing symptomatic COVID-19 by 83% compared to placebo.

“The AZD7442 PROVENT trial is the first phase III trial prospectively designed to evaluate a monoclonal antibody for the pre-exposure prophylaxis of symptomatic COVID-19, with a targeted inclusion of high-risk and immunosuppressed participants. Over 75% of PROVENT participants at baseline had co-morbidities that put them at high risk of severe COVID-19 if they were to become infected, including people who are immunocompromised and may have a reduced immune response to vaccination, ”said writes AstraZeneca.

There have been no cases of serious death from COVID-19 or COVID-19 in people treated with AZD7442 at initial scans or at six months.

In this Wednesday March 10, 2021, file photo, a health worker administers a dose of AstraZeneca vaccine against COVID-19 to a patient inside the convention center known as “La Nuvola”, The Cloud, in Rome.
(AP Photo / Andrew Medichini, dossier)

Comparatively, in the placebo arm, there were two additional cases of severe COVID-19 at the six-month assessment and five in total. There have also been two COVID-related deaths.

Exploratory analysis of a separate treatment trial – the Tackle outpatient treatment trial – found that a 600 mg intramuscular dose of AZD7442 reduced the risk of patients with mild to moderate COVID-19 developing by 88% severe or dead COVID-19, compared to placebo in patients who had symptoms for three days or less at the time of treatment.

SEVERAL CALIFORNIA CHILDREN SICK AFTER GIVING BAD COVID-19 VACCINE DOSE

AstraZeneca noted that 90% of participants enrolled in Tackle were from populations at high risk of progressing to severe COVID-19 if they became infected, including those with co-morbidities.

“In PROVENT and TACKLE, AZD7442 was generally well tolerated, ”he said. “No new safety issues were identified in PROVENT’s six-month analysis. ”

“AZD7442 is the only long-acting antibody with phase III data to demonstrate benefit in both pre-exposure prophylaxis and treatment of COVID-19 with one dose. These new data add to the growing body of evidence supporting AZD7442’s potential to make a significant difference in the prevention and treatment of COVID-19, ”said Mene Pangalos, executive vice president of research and of biopharmaceutical development at AstraZeneca, in a press release. “We are making progress on regulatory files around the world and look forward to delivering an important new option against SARS-CoV-2 as soon as possible. “

Full results from both trials will be submitted for publication in a peer-reviewed medical journal and presented at an upcoming medical meeting.

CLICK HERE TO GET THE FOX NEWS APP

In October, AstraZeneca announced that it had submitted an application to the Food and Drug Administration for an emergency use authorization for AZD7442 – or Evusheld – “for COVID-19 prophylaxis.”

If regulators give the green light, the company has pledged to provide the US government with 700,000 doses of AZD7442.

LEAVE A REPLY

Please enter your comment!
Please enter your name here